Hari Deshpande, MD
Research & Publications
Biography
News
Research Summary
I have been involved in clinical trials since joining Yale in 2004. My main interests are in sarcoma, thyroid cancers and cancers of unknown primary. I am also part of the head and neck and GU cancer teams and participate in their trials. My current research includes new treatments for thyroid cancers as well as types of sarcoma. I will also be also looking at the effect of COVID on the inpatient medical oncology consult service at Yale. I am fortunate to be an investigator in over 20 trials of different therapies in Sarcomas, head and neck cancers, thyroid cancers and GU cancers
Extensive Research Description
The clinical trials I am involved with change frequently - I encourage interested people to view the Yale Cancer Center Clinical Trials website. http://yalecancercenter.org/patient/trials/
Sarcoma; Cancers of unknown primary; Thyroid cancer
Coauthors
Research Interests
Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Soft Tissue Neoplasms; Sarcoma, Synovial; Thyroid Neoplasms; Neoplasms, Connective and Soft Tissue; Liposarcoma, Myxoid
Selected Publications
- Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma.Hasan NM, Sharma A, Ruzgar NM, Deshpande H, Olino K, Khan S, Ahuja N. Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma. Oncotarget 2021, 12: 1566-1579. PMID: 34381562, PMCID: PMC8351604, DOI: 10.18632/oncotarget.28032.
- Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2022, JCO2101829. PMID: 35394800, DOI: 10.1200/JCO.21.01829.
- Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients.Forman R, Deshpande H, Burtness B, Bhatia AK. Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 2022 PMID: 35488876, DOI: 10.1002/hed.27077.